109 related articles for article (PubMed ID: 15124702)
1. Evolution of BFM trials for childhood ALL.
Schrappe M
Ann Hematol; 2004; 83 Suppl 1():S121-3. PubMed ID: 15124702
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
3. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
5. [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)].
Riehm H; Reiter A; Schrappe M; Berthold F; Dopfer R; Gerein V; Ludwig R; Ritter J; Stollmann B; Henze G
Klin Padiatr; 1987; 199(3):151-60. PubMed ID: 3306129
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia.
Schrappe M
Radiat Prot Dosimetry; 2008; 132(2):130-3. PubMed ID: 19017727
[TBL] [Abstract][Full Text] [Related]
9. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
10. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter.
Lauten M; Stanulla M; Zimmermann M; Welte K; Riehm H; Schrappe M
Klin Padiatr; 2001; 213(4):169-74. PubMed ID: 11528550
[TBL] [Abstract][Full Text] [Related]
12. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
13. Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study Group.
Stanulla M; Cario G; Meissner B; Schrauder A; Möricke A; Riehm H; Schrappe M
Blood Cells Mol Dis; 2007; 39(2):160-3. PubMed ID: 17532236
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
15. [Monitoring minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Zuna J; Hrusák O; Kalinová M; Muzíková K; Zörnerová T; Starý J; Trka J
Vnitr Lek; 2000 Aug; 46(8):465-9. PubMed ID: 11048511
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
Klimza MJ; Sońta-Jakimczyk DJ
Wiad Lek; 2005; 58(11-12):622-5. PubMed ID: 16594471
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in childhood acute lymphoblastic leukemia.
Schrappe M
Indian J Pediatr; 2003 Oct; 70(10):817-24. PubMed ID: 14649479
[TBL] [Abstract][Full Text] [Related]
19. Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease.
Steinemann D; Cario G; Stanulla M; Karawajew L; Tauscher M; Weigmann A; Göhring G; Ludwig WD; Harbott J; Radlwimmer B; Bartram C; Lichter P; Schrappe M; Schlegelberger B
Genes Chromosomes Cancer; 2008 Jun; 47(6):471-80. PubMed ID: 18311775
[TBL] [Abstract][Full Text] [Related]
20. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
